about
Eslicarbazepine acetate add-on for drug-resistant partial epilepsyEslicarbazepine acetate add-on for drug-resistant partial epilepsyA review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsyUpdate on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyRecent treatment advances and novel therapeutic approaches in epilepsyIon channels as drug targets in central nervous system disordersNew and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapyRole of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.Pharmacokinetics and drug interactions of eslicarbazepine acetate.Update on treatment of partial onset epilepsy: role of eslicarbazepinePractice Update: Review of Anticonvulsant Therapy.Emerging drugs for epilepsy.Clinical utility of eslicarbazepine: current evidence.Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapyNew and investigational antiepileptic drugs.Drug interactions involving the new second- and third-generation antiepileptic drugs.Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.Emerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Second-generation antiepileptic drugs and pregnancy: a guide for clinicians.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.[Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine.Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
P2860
Q24234598-BE736691-D1B8-4C84-8F5C-99188F02EDD6Q24235938-DEBA8B1F-5BFC-452F-A342-32B66059E96CQ24621327-B9918456-1085-476F-92B4-72176046E001Q26745780-EB344A8A-0DA8-41C8-AA28-777C9F842AC3Q26824512-46F06F80-4223-48F5-9578-A65A296544CAQ27004533-D3D9CF4C-5D6F-44D7-9BDA-3F81DE0DFEF1Q27007942-6F63803A-3EBF-46D3-B3E8-64D46C2F14DFQ33802172-12FC094B-BD18-42E3-993C-ADD2800E62C0Q34276263-CB237242-3A4B-449E-9820-21444F7B245EQ34329823-E659C396-B5F0-4E54-AC87-E2FB28A1B7A2Q34518509-60B8C161-3852-420D-B64A-06AB3B39B171Q34688725-69EFC8B9-1EC9-4746-B3C5-098E4AB1665BQ35087964-B143A05F-D370-4194-A07A-B29BA03DC27AQ35664957-7B4E7CF8-B20D-4407-9797-DBC91C920B72Q35761335-82938A5C-F35F-42EB-ADBD-67E186CF28AEQ35936036-EC9FBCA8-63A6-4B13-BB73-EC64BCB1FA40Q37638688-5255AB1C-5E6D-4EC0-9174-5286376F436CQ37658910-6CE74908-EB48-4F15-87DB-752C78359509Q37680030-C8C2D3BD-46BD-42D0-9B9D-CCD881B70FDDQ37694387-9B918CF4-09A2-4FEB-820F-061B1C780A59Q37754477-FBFA4D15-C061-48CE-AFD9-999723219062Q37831297-F2E79CB0-F416-4E34-97FD-FB20012BF482Q37950518-4C17362C-0F7B-4FC6-A93F-ED9C3B5474ADQ37957121-A7558E7A-F92B-497B-80AB-FA380FFF0745Q37992162-BDA671EE-55FB-43A4-98CA-C01EFE9474E0Q38014890-D3C36F9F-93CC-4812-B836-3B1F377B160BQ38223958-ABEC2BFF-9811-4DF5-9541-6B4C523774C9Q38367761-13BEF010-6475-4DCA-8B49-6186ED39DED1Q38656011-AB96BBC9-38B5-4709-9136-C972DFF03E09Q38800995-DA2219F1-921F-4874-8980-7D8BF0F3EB83Q39116160-4CC1A1C3-C7D9-4D8D-8AC8-31E309E06709Q40611807-31AF08BF-A084-407E-95F9-348672F79E64Q41984278-C6B61997-D308-46DC-B504-7C08E76B2DA4Q42956261-9344CA12-8BFB-419E-990B-EE2562BFE80FQ43005474-D7CD8E13-DB42-4757-B49D-93CCFC8F7D1EQ44062629-9FD99DFC-4AEA-4212-ADC2-5B5CBCC8BEACQ46570612-4EC4E1E7-E4BE-4F27-9F2F-83689CA070C5Q47235722-93EFD3B4-949D-4BC1-9F3A-862875D5C78CQ47724046-7C1973B1-3696-490D-8734-A1C95B709C8EQ48352462-9DDCE7C5-E514-4399-931D-F7DE5E5F51E4
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Eslicarbazepine acetate (BIA 2-093).
@ast
Eslicarbazepine acetate (BIA 2-093).
@en
Eslicarbazepine acetate
@nl
type
label
Eslicarbazepine acetate (BIA 2-093).
@ast
Eslicarbazepine acetate (BIA 2-093).
@en
Eslicarbazepine acetate
@nl
prefLabel
Eslicarbazepine acetate (BIA 2-093).
@ast
Eslicarbazepine acetate (BIA 2-093).
@en
Eslicarbazepine acetate
@nl
P2860
P1433
P1476
Eslicarbazepine acetate (BIA 2-093)
@en
P2093
Luis Almeida
Patrício Soares-da-Silva
P2860
P2888
P356
10.1016/J.NURT.2006.10.005
P577
2007-01-01T00:00:00Z
P5875
P6179
1016988613